Conversely, pharmacological inhibition of PRKCD or depletion by siRNA is sufficient to prevent dopaminergic neurodegeneration in PD models [59], [60] pointing to PRKCD inhibition as a neuroprotective strategy for PD. This evidence concerns the gene PRKCD and Parkinson disease.